Postoperative Pain Control With Lipossomic Extended Release Bupivacaine

University of Tennessee

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Pain, Postoperative; Lung Cancer

Treatments: Drug: Bupivacaine / Epinephrine; Drug: Bupivacaine liposome

Study type: Interventional

Funder types: Other

Identifiers

NCT03560362

15-03838

Details and patient eligibility

About

Randomized trial of intraoperative intercostal block with bupivacaine with epinephrine compared to lipossomal extended release bupivacaine.

Full description

Patients undergoing minimally invasive thoracic surgery will be randomized to receive 0.05% bupivacaine with 1:200,000 epinephrine (control group) or extended release lipossomal bupivacaine. Primary outcomes are postoperative pain measured by visual analog scale, amount of morphine equivalent narcotics used, and postoperative complications. Patients are excluded if they undergo open thoracotomy, or minimally invasive decortication.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Patients who will be undergoing minimally invasive thoracic surgery

• Patients who will be undergoing minimally invasive thoracic surgery

Exclusion Criteria:

• Open surgery
• Chronic use of narcotics
• Use of pregabalin or similar
• Significant liver or kidney dysfunction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

Bupivacaine with epinephrine

Active Comparator group

Description:

Patients will receive intraoperative intercostal nerve block with bupivacaine

Treatment:

Drug: Bupivacaine / Epinephrine

Lipossomal extended release bupivacaine

Experimental group

Description:

Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine

Treatment:

Drug: Bupivacaine liposome